LARIMAR THERAPEUTICS, INC. (LRMR)
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
📈 **POSITIVE** • High confidence analysis (83%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (92%) **Content type:** Clinical